• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Mesoblast Limited

    9/16/25 7:22:32 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MESO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    MESOBLAST LTD

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    590717401

    (CUSIP Number)


    09/12/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    590717401


    1Names of Reporting Persons

    Gueck William J.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    525,000.00
    6Shared Voting Power

    63,996,900.00
    7Sole Dispositive Power

    525,000.00
    8Shared Dispositive Power

    63,996,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    64,521,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  (1) The number of Ordinary Shares reported is as of September 12, 2025. The Reporting Person is the sole beneficial owner of 525,000 Ordinary Shares held in the form of American Depositary Receipts ("ADRs"). The Reporting Person also has discretionary authority to vote and dispose, and may be deemed to be the beneficial owner, of: (i) 1,792,150 Ordinary Shares held in the form of ADRs by Conrad Gueck; (ii) 1,792,150 Ordinary Shares held in the form of ADRs by Ava Gueck; (iii) 1,110,000 Ordinary Shares held in the form of ADRs by the Mary DeAnn Gueck trust, for which the Reporting Person is trustee; (iv) 890,000 Ordinary Shares held in the form of ADRs by the William Gueck trust, for which Mary DeAnn Gueck is trustee. In addition, the Reporting Person has discretionary authority to vote and dispose of (A) 49,717,450 Ordinary Shares held in the form of ADRs by Cova Holdings LP and (B) 350,000 Ordinary Shares in the form of ADRs underlying warrants that Cova Holdings LP has the right to acquire through the exercise of such warrants within 60 days, and may be deemed to be the beneficial owner of these shares. In addition, the Reporting Person has discretionary authority to vote and dispose of 8,345,150 Ordinary Shares held in the form of ADRs by AVCO Holdings LP and may be deemed to be the beneficial owner of these shares.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MESOBLAST LTD
    (b)Address of issuer's principal executive offices:

    Level 38, 55 Collins Street, Melbourne, VIC, Australia, 3000
    Item 2. 
    (a)Name of person filing:

    This statement is filed by Dr. William Gueck (the "Reporting Person").
    (b)Address or principal business office or, if none, residence:

    Dr. William Gueck 54 Roan Ln St. Louis, MO, 63124
    (c)Citizenship:

    Dr. William Gueck is a citizen of the United States of America.
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    590717401
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The percentages used herein are calculated based upon 1,281,167,187 Ordinary Shares issued and outstanding as of August 25, 2025, based on information provided by an officer of the Issuer in an email correspondence on August 25, 2025. The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for the Reporting Person and is incorporated herein by reference. The Reporting Person's total beneficial ownership amounts to 64,521,900 Ordinary Shares held in the form of ADRs (constituting approximately 5.0% of the Ordinary Shares outstanding). The Reporting Person is the sole beneficial owner of 525,000 Ordinary Shares held in the form of ADRs. The Reporting Person also has discretionary authority to vote and dispose, and may be deemed to be the beneficial owner, of: (i) 1,792,150 Ordinary Shares held in the form of ADRs by Conrad Gueck; (ii) 1,792,150 Ordinary Shares held in the form of ADRs by Ava Gueck; (iii) 1,110,000 Ordinary Shares held in the form of ADRs by the Mary DeAnn Gueck trust, for which the Reporting Person is trustee; (iv) 890,000 Ordinary Shares held in the form of ADRs by the William Gueck trust, for which Mary DeAnn Gueck is trustee. In addition, the Reporting Person has discretionary authority to vote and dispose of (A) 49,717,450 Ordinary Shares held in the form of ADRs by Cova Holdings LP and (B) 350,000 Ordinary Shares in the form of ADRs underlying warrants that Cova Holdings LP has the right to acquire through the exercise of such warrants within 60 days, and may be deemed to be the beneficial owner of these shares. In addition, the Reporting Person has discretionary authority to vote and dispose of 8,345,150 Ordinary Shares held in the form of ADRs by AVCO Holdings LP and may be deemed to be the beneficial owner of these shares. Although the Reporting Person may be deemed to have beneficial ownership of such Ordinary Shares, neither the filing of this Schedule 13G nor any of the contents hereof shall be deemed to constitute an admission by the Reporting Person that he is the beneficial owner of any of the Ordinary Shares owned by Cova Holdings LP and by AVCO Holdings LP for purposes of Section 13(d) of the Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
    (b)Percent of class:

    N/A
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    N/A

     (ii) Shared power to vote or to direct the vote:

    N/A

     (iii) Sole power to dispose or to direct the disposition of:

    N/A

     (iv) Shared power to dispose or to direct the disposition of:

    N/A

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Gueck William J.
     
    Signature:/s/ William Gueck
    Name/Title:Dr. William Gueck
    Date:09/16/2025
    Get the next $MESO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MESO

    DatePrice TargetRatingAnalyst
    7/18/2025Buy → Hold
    Jefferies
    12/23/2024Buy → Hold
    Jefferies
    9/24/2024$12.00Hold → Buy
    Maxim Group
    8/29/2024Hold → Buy
    Jefferies
    7/23/2024$4.00 → $11.00Neutral → Overweight
    Piper Sandler
    8/31/2023Hold → Buy
    Jefferies
    8/7/2023Buy → Hold
    Maxim Group
    8/4/2023$7.00 → $2.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $MESO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs

    NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products. Ryoncil® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company's Biologic License Application (BLA), Ryoncil® is designated a ‘U.S. Country of Origin' product in line with U.S. FDA and Customs

    9/26/25 1:49:36 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences

    NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York. Mesoblast Chief Executive Silviu Itescu reiterated the strong first quarter launch of Ryoncil® and product sales in the treatment of children with steroid-refractory acute graft versus host

    9/14/25 9:18:56 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

    NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck ("Investors") to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblast's option, following shareholder approval, to repay or reduce the amount owing to its secured lenders under the existing loan agreements and for general working capital purposes. Mesoblast Chief Executive

    9/3/25 9:47:05 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mesoblast downgraded by Jefferies

    Jefferies downgraded Mesoblast from Buy to Hold

    7/18/25 8:10:38 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mesoblast downgraded by Jefferies

    Jefferies downgraded Mesoblast from Buy to Hold

    12/23/24 7:24:07 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mesoblast upgraded by Maxim Group with a new price target

    Maxim Group upgraded Mesoblast from Hold to Buy and set a new price target of $12.00

    9/24/24 8:11:34 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MESO
    SEC Filings

    View All

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    9/29/25 7:22:09 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Mesoblast Limited

    SCHEDULE 13G - MESOBLAST LTD (0001345099) (Subject)

    9/16/25 7:22:32 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Mesoblast Limited

    6-K - MESOBLAST LTD (0001345099) (Filer)

    9/15/25 7:48:07 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MESO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    10/9/24 3:42:14 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    7/11/24 7:38:31 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MESO
    Leadership Updates

    Live Leadership Updates

    View All

    Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025

    NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third quarter ended March 31, 2025. "We were very pleased to have made Ryoncil® (remestemcel-L) commercially available to treat children with acute GVHD within one quarter of receiving FDA approval as the first mesenchymal stromal cell (MSC) therapy approved in the US for any indication," said Dr. Silviu Itescu, CEO of Mesoblast. "With our strong cash position we are well placed to expand Ryoncil® indications to other serious and life-threatening pediatric inflammatory di

    4/29/25 8:53:27 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board

    NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Lyn Cobley to its Board of Directors. Ms. Cobley has been a global leader in the financial services industry with over 30 years' experience in senior positions at international and domestic banks. Ms. Cobley has served as CEO of Westpac Institutional Bank, Group Treasurer of Commonwealth Bank of Australia, and held senior roles at Barclays Capital and Citibank Limited. Ms. Cobley is currently a director of Commonwealth Bank of Australia, is a member of Chief Executive Women, a member of the Macquarie

    4/28/25 7:44:18 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Dr. Gregory George MD PhD Joins Mesoblast Board

    NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Dr. Gregory George MD PhD, Mesoblast's largest shareholder, to its Board of Directors. Dr. George founded and managed the largest privately owned ambulatory surgical center company in the United States, SurgCenter Development. Dr. George brings to the Board his background as a medical scientist with unique operational experience having built a start-up company in the medical field and turning it into a highly-efficient multi-billion-dollar commercial organization. Mesoblast Founder and Chief

    2/23/25 6:33:52 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MESO
    Financials

    Live finance-specific insights

    View All

    Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024

    NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended June 30, 2024. Mesoblast Chief Executive Silviu Itescu said: "During the past year we have built significant momentum in our interactions with the United States Food and Drug Administration (FDA) across each of our Phase 3 products. I am very pleased that our Biologics License Application (BLA) resubmission for approval of Ryoncil® (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD)

    8/28/24 7:27:43 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

    NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational update and reported financial results for the period ended December 31, 2023. Mesoblast Chief Executive Silviu Itescu said: "We were very busy operationally during the last quarter and continued to have positive engagement with the United States Food and Drug Administration (FDA) across our lead programs. We have strengthened our balance sheet while maintaining overall spending constraint in line with our corporate objectives. For our product Ryoncil® (remestemcel-L) for life-threatening steroid-ref

    2/28/24 5:57:09 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023

    NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB))), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: "We had anticipated that remestemcel-L would have been approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a condition with a high mortality where there are no approved therapies for children under 12 years old. During the six-month B

    8/30/23 7:07:02 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care